Sagimet Biosciences Inc. (NASDAQ:SGMT – Get Free Report) has earned a consensus rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat.com reports. Seven equities research analysts have rated the stock with a buy rating. The average 1-year price objective among analysts that have issued a report on the stock […]

Related Keywords

United States , Leerink Partnrs , David Happel , Sagimet Biosciences , Hermes Inc , Silverarc Capital Management , Nasdaq , Sagimet Biosciences Inc , Platinum Investment Management Ltd , Sagimet Biosciences Company Profile , Goldman Sachs Group , Get Free Report , Investment Management , Capital Management , Rock Springs Capital Management , Get Free , Biosciences Inc , Sagimet Biosciences Daily ,